These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15039681)

  • 21. Why we work with the tobacco industry.
    Hughes JR; Fagerstrom KO; Henningfield JE; Rodu B; Rose JE; Shiffman S
    Addiction; 2019 Feb; 114(2):374-375. PubMed ID: 30324665
    [No Abstract]   [Full Text] [Related]  

  • 22. Smokeless tobacco products: Unrecognised regulatory and policy opportunities.
    Gartner CE; Hall WD
    Drug Alcohol Rev; 2010 Mar; 29(2):119-20. PubMed ID: 20447217
    [No Abstract]   [Full Text] [Related]  

  • 23. Ethically Problematic Medical Device Representation.
    Illes J; McDonald PJ; Lau C; Hrincu VM; Connolly MB
    Am J Bioeth; 2020 Aug; 20(8):5-6. PubMed ID: 32757913
    [No Abstract]   [Full Text] [Related]  

  • 24. Nightingales vs. big tobacco: nurses confront the nation's greatest public health threat.
    Schwarz T
    Am J Nurs; 2004 Jun; 104(6):27. PubMed ID: 15187604
    [No Abstract]   [Full Text] [Related]  

  • 25. Mistrusting companies, mistrusting the tobacco industry: clarifying the context of tobacco prevention efforts that focus on the tobacco industry.
    Thrasher JF; Jackson C
    J Health Soc Behav; 2006 Dec; 47(4):406-22. PubMed ID: 17240928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
    Kozlowski LT
    Am J Prev Med; 2007 Dec; 33(6 Suppl):S379-86. PubMed ID: 18021913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advocacy in action: extreme corporate makeover interruptus: denormalising tobacco industry corporate schmoozing.
    Chapman S
    Tob Control; 2004 Dec; 13(4):445-7. PubMed ID: 15564635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spin cycles. Healthcare marketing-communications efforts have taken on increasing strategic importance.
    Romano M
    Mod Healthc; 2005 Nov; 35(47):28-30. PubMed ID: 16334365
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of modified risk tobacco product claims on beliefs of US adults and adolescents.
    El-Toukhy S; Baig SA; Jeong M; Byron MJ; Ribisl KM; Brewer NT
    Tob Control; 2018 Nov; 27(Suppl 1):s62-s69. PubMed ID: 30158212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Planting trees without leaving home: tobacco company direct-to-consumer CSR efforts.
    Gonzalez M; Ling PM; Glantz SA
    Tob Control; 2012 May; 21(3):363-5. PubMed ID: 22193045
    [No Abstract]   [Full Text] [Related]  

  • 31. An analysis of tobacco industry marketing to lesbian, gay, bisexual, and transgender (LGBT) populations: strategies for mainstream tobacco control and prevention.
    Stevens P; Carlson LM; Hinman JM
    Health Promot Pract; 2004 Jul; 5(3 Suppl):129S-134S. PubMed ID: 15231106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Too friendly? Teaching hospitals revisit ties to pharmaceutical firms.
    Romano M
    Mod Healthc; 2003 Jul; 33(28):17. PubMed ID: 12884711
    [No Abstract]   [Full Text] [Related]  

  • 33. The Virginia Slims identity crisis: an inside look at tobacco industry marketing to women.
    Toll BA; Ling PM
    Tob Control; 2005 Jun; 14(3):172-80. PubMed ID: 15923467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Marketing and the HPV vaccine.
    Massad LS
    JAMA; 2009 Dec; 302(24):2660; author reply 2661. PubMed ID: 20040551
    [No Abstract]   [Full Text] [Related]  

  • 35. Young adults' perceptions about established and emerging tobacco products: results from eight focus groups.
    Wray RJ; Jupka K; Berman S; Zellin S; Vijaykumar S
    Nicotine Tob Res; 2012 Feb; 14(2):184-90. PubMed ID: 22110049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Which cigarettes do Americans think are safer? A population-based analysis with wave 1 of the PATH study.
    Leas EC; Ayers JW; Strong DR; Pierce JP
    Tob Control; 2017 Mar; 26(e1):e59-e60. PubMed ID: 27742918
    [No Abstract]   [Full Text] [Related]  

  • 37. Industry support and professional medical associations.
    Smith CD; Buyske J; Talamini MA
    JAMA; 2009 Aug; 302(7):738-9; author reply 739. PubMed ID: 19690303
    [No Abstract]   [Full Text] [Related]  

  • 38. Learning from truth: youth participation in field marketing techniques to counter tobacco advertising.
    Eisenberg M; Ringwalt C; Driscoll D; Vallee M; Gullette G
    J Health Commun; 2004; 9(3):223-31. PubMed ID: 15360035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study affirms PhRMA's influence on physicians.
    Miller JD
    J Natl Cancer Inst; 2007 Aug; 99(15):1148-50. PubMed ID: 17652272
    [No Abstract]   [Full Text] [Related]  

  • 40. "What Is Our Story?" Philip Morris's Changing Corporate Narrative.
    McDaniel PA; Malone RE
    Am J Public Health; 2015 Oct; 105(10):e68-75. PubMed ID: 26270280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.